Perlara partners with third patient advocacy group

Tuesday, January 31, 2017

Perlara, a global patient portal and drug discovery platform company for the one in 10 families affected by rare disease, has announced the formation of a PerlQuest partnership with Michigan-based Maggie’s PMM2-CDG Cure. PMM2-CDG, formerly known as congenital disorder of glycosylation type 1a, is caused by mutations in the evolutionarily conserved gene PMM2. There are currently no FDA approved treatments for PMM2-CDG.

[Read More]